M etastases from breast cancer often involve locoregional and distant lymph nodes, lung, bone, liver, and brain. 1 Metastatic involvement of the gastrointestinal tract is unusual, but the frequency of esophageal and mediastinal metastases from breast cancer is probably underestimated. According to Asch et al (autoptic study), 2 their incidence ranges between 5% and 6% among women dying of advanced breast cancer, which would suggest a clinically silent esophageal involvement in a considerable number of patients.
Metastases to the inner (mucosal and submucosal) layers of the esophageal wall are extremely rare 3 ; indeed, esophageal involvement is usually due to mediastinal carcinomatosis. Many such lesions develop several years after the primary breast cancer has been treated and can be mistaken for a second primary. Esophageal or mediastinal metastases from breast cancer are usually asymptomatic, 2,4 but a clinical syndrome may develop, with progressively worsening dysphagia, after a long disease-free interval (up to 22 years 4 ) since mastectomy. The corresponding peculiar radiologic and endoscopic picture is a concentric stricture of the esophagus covered by normal mucosa due to the involvement of the esophageal wall from the outside inwards, usually in the middle and lower thirds of the esophagus.
We report here on 25 cases of dysphagia due to esophageal stricture in patients with metastatic breast cancer of the esophagus, discussing the difficulties encountered in identifying and staging these malignancies in the mediastinum and the corresponding treatment options.
MATERIALS AND METHODS
In a series of 4198 cases of malignant esophageal disease observed between 1980 and April 2006, 114 (2.7%) were metastases from nonesophageal primaries (thyroid, lung, bronchi, lymphoma, colon, uterus, breast, and oral cavity).
The breast was the site of the primary tumor in 25 patients (0.6%), with a median age of 58 years (interquartile range ͓IQR͔, 56 -67 years). All but one had undergone surgery for breast cancer a median of 10 years (IQR, 8 -17 years) before presenting with esophageal involvement. Seventeen of the 25 patients (68%) had been given postoperative adjuvant radiotherapy or telecobalt therapy.
All patients were referred for worsening dysphagia lasting a median 8 months (IQR, 5-12 months); 14 (56%) reported a weight loss greater than 10%; 3 (12.5%) had dysphonia.
Details on their previous treatments for breast cancer and clinicopathologic characteristics of their esophageal secondaries are given in Table 1 .
All cases were studied by means of barium swallow and upper endoscopy. Most patients also had computed tomography (CT) of the chest and abdomen. From 1995 onwards, endoscopic ultrasound was used selectively to better define the extent of esophageal involvement. More recently, minimally invasive exploratory thoracoscopy has been used, where necessary, to facilitate the diagnosis.
The final diagnosis was based on the histologic assessment of biopsy samples, wherever possible. More recently, immunohistological staining has become available to detect estrogen receptor (ER), progesterone receptor (PgR), c-erb, and cytokeratin expressions.
Statistical Analysis
Data are expressed as medians and IQRs. Proportions were compared using the 2 or Fisher exact test. Continuous variables were compared using the Mann-Whitney U test. Survival estimates were calculated by the Kaplan-Meier method and survival comparisons were performed using the log-rank test. A P value below 0.05 was considered significant.
RESULTS
Based on barium swallow studies ( Fig. 1 ), the mid-(13 of 25, 52%) or lower third (7 of 25, 28%) of the esophagus was usually affected ( Table 2 ). The median length of the esophageal stricture was 5 cm (IQR, 3-6 cm). All but 1 patient had endoscopy, which revealed the extrinsic esophageal wall involvement with an apparently normal mucosal layer. Endoscopic biopsy sampling or brush cytology was done in all but 6 patients, which were negative for cancer in 17 of 19 (89%). Endoscopic ultrasound was performed in 6 patients, revealing thickening of the esophageal wall in 4 and periesophageal lymphadenopathy in 2 (1 patient had both) ( Fig. 2 ). CT scans of the chest and abdomen were performed in 14 patients and disclosed a circumferential thickening of the esophageal wall and/or mediastinal lymph node enlargement ( Fig. 3) . One patient had a positron emission tomography scan, which showed an increased SUV (standardized uptake value) in the paramediastinal region. Breast cancer markers (MCA, Ca 15.3, Ca 125) were evaluated in 10 of 25 cases (40%) and at least one was above normal limits in 5 of 10 cases (50%). Nine cases were diagnosed after minimally invasive exploratory thoracoscopy (n ϭ 5) or laparoscopy (n ϭ 4). Immunohistochemical staining ( Fig. 4 ) was done in 10 patients and was positive for ER and/or PgR.
Fifteen patients (60%) also presented with other, nonmediastinal metastases involving: liver (3), lung and supraclavicular and axillary lymph nodes (1), skin (4), bone (4), liver and bone (1), bone and supraclavicular lymph nodes (1), skin and bone (1). The tracheobronchial tree was also affected in 2 patients.
Treatment focused mainly on palliation of dysphagia (Table 3 ). During the initial period, up until 1990, this consisted (in 11 patients) of endoscopic dilation (4 cases), endoscopic positioning of a prosthesis (4 cases) feeding gastrostomy (2 cases); 3 patients were given cytoreductive therapy, which was the only treatment in 1 case. All the complications seen were endoscopic perforations (after dila-tion in 2, after positioning a prosthesis in 1), which were treated as follows: bipolar exclusion and cervical retrosternal esophagogastroplasty in the first patient, who died of respiratory insufficiency during the postoperative period; cervical drainage, gastrostomy and a prosthesis to exclude the fistula in the second; and conservative treatment in the third.
In the latter period, since 1990 (14 patients), treatment has consisted of: endoscopic dilation (3), endoscopic prosthesis (3), gastrostomy (1), and Heller's myotomy (1 patient with instrumental and functional test suggestive of achalasia); 11 patients were given cytoreductive therapy, which was the only treatment in 6 cases. Complications included one endoscopic perforation after positioning a prosthesis with a tracheoesophageal fistula, which was treated with a bipolar exclusion and subcutaneous gastroesophageal bypass.
Nine of the 11 patients treated before 1990 had distant metastases (81.8%), as opposed to 6 of 14 (42.9%) treated after 1990 (P ϭ not significant). Three patients (27.3%) presenting before 1990 were given cytoreductive therapy, versus 11 of 14 patients (78.6%) after 1990 (P ϭ not significant).
Patients treated before 1990 survived a median 3 months, while for those treated afterward the median survival was 17.5 months (P ϭ not significant). Nine patients are still alive, and 16 have died. The median survival for the whole series was 7 months (IQR, 1-26 months); the 1-, 3-, and 5-year actuarial survival rates were 46%, 16%, and 8%, respectively.
Patients who were given cytoreductive therapy (chemoradiotherapy and/or hormone therapy) survived a median 16 months, as opposed to 4.5 months for those who were not (P ϭ not significant).
Patients with mediastinal/pleural metastases alone survived a median 19 months, while those with other remote metastases survived 3 months (P ϭ not significant).
DISCUSSION
Metastatic esophageal disease from previously treated breast cancer has been estimated to account for 0.4% of all cases of symptomatic esophageal obstruction. 5 The majority of symptomatic cases of involvement of the outer layers of the esophageal wall (secondary to breast cancer) are due to mediastinal carcinosis, while metastases to the inner layers of the esophagus are extremely rare. 6 Patients with metastatic breast carcinoma present clinically with dysphagia even several years after being treated for breast cancer: in our series, this interval was 10 years (median). Associated symptoms include weight loss, anorexia, or dysphonia. In some cases, the clinical presentation may mimic achalasia 7 or nonspecific esophageal motility disorder. 8 Metastatic lesions are most often found in the middle or distal thirds of the esophagus, as confirmed in this series. Most patients are postmenopausal. 3 The mechanism behind esophageal spread from breast cancer is controversial. We found an infiltration of the mediastinal pleura with esophageal tissue involvement. The spread of the disease is most likely lymphatic, through the intercostal vessels, to reach the internal mammary chain and the mediastinal lymph nodes, thus the intramural lymphatics of the esophagus, with subsequent stenosis of the esophagus. The involvement of the intertracheobronchial lymph nodes and the lymphatic connections in the mediastinum would explain why the middle third of the esophagus is the most frequent site of stenosis in these patients. 10 That is why most authors use the expression "mediastinal localization" rather than "esophageal metastasis" to describe this condition. There are only a few reports of "true" esophageal metastases from breast cancer. 6 Breast cancer may also infiltrate intramurally within the esophagus and disrupt its motility by obliterating nerve plexuses as well as the normal esophageal architecture. 3 It is a challenge to diagnose an esophageal stricture due to esophageal involvement from breast cancer, and it is particularly difficult to differentiate between primary esophageal tumor, postactinic stenosis, peptic stricture, and mediastinal carcinomatosis. In our experience, when patients were diagnosed as having an esophageal primary, they had already been suffering from dysphagia for about 3 months, whereas patients with secondary esophageal cancer had been experiencing this symptom for approximately 8 months (P ϭ 0.001). At the time of admission, only 20% of cases (2 of 10) had a diagnosis of neoplastic mediastinitis, in 50% (5 of 10), it was esophageal stenosis not otherwise specified; in 20% (2 of 10), it was esophageal carcinoma; and in 10% (1 of 10), it was achalasia. The presence of distant metastases makes it easier to diagnose esophageal involvement due to mediastinal carcinosis, whereas patients presenting with a mediastinal and/or pleural diffusion alone pose considerable diagnostic difficulties. The distinction lies in establishing whether it is a case of primary esophageal cancer, a postactinic stenosis, or a metastasis to the mediastinum. In this subgroup of patients, minimally invasive exploratory thoracoscopy is mandatory to reach a definitive diagnosis, although in experienced hands, EUS-FNAB could be a valid alternative. In our experience of 709 female patients with the cancer of the esophagus, 31 (4.4%) had a positive history of breast cancer. Of these, 13 (42%) had received radiotherapy. Thus, this value would support in part the hypothesis that women who have radiotherapy to the breast are at greater risk of developing esophageal cancer. 11 The diagnosis of esophageal involvement depends on a clinical history of breast cancer. Several imaging methods can be helpful, ie, barium swallow, endoscopy, endosonography, CT scan. On the other hand, although the definitive diagnosis should be founded on a histologic assessment, endoscopic biopsies are usually negative for cancer.
EUS-guided FNAB is reported useful as a diagnostic alternative to exploratory surgery, 12 enabling cytologic and histopathologic specimens to be obtained from lymph nodes and mediastinal masses suspected of malignancy. In our experience, a histopathologic diagnosis demanded thoracoscopy and biopsy of the mediastinal periesophageal tissue and/or pleura in 5 cases and laparoscopy in 4. In a few patients, when biopsy samples were negative for cancer, an ex adjuvantibus diagnosis was reached on the basis of dysphagia relief after hormone therapy and/or chemotherapy and/or radiotherapy.
The histopathologic diagnosis is important to assess the pattern and degree of atypia and for evaluating ER and PR expression.
By the time symptoms appear, the majority of patients already have distant metastases and the treatment is usually aimed to palliation of dysphagia. Endoscopic treatment seems the most logical but is not usually indicated because of the high risk of perforation. In our series, the perforation rate after endoscopic treatment with dilations or prostheses was as high as 26.7% versus 4.4% (28 of 638) among patients with primary esophageal cancer treated during the same period at our department (P ϭ 0.004). More recently, expandable metal stents have been found a safe and effective treatment of esophageal obstruction caused by inoperable cancer. 13 A metastatic lesion in the esophagus with a short stenosis may be a valid indication for stent placement, but extreme caution is mandatory because the tissue is relatively inelastic and there is a risk of severe complications. The safety of this approach needs to be confirmed in patients with esophageal stricture secondary to breast cancer. In our opinion, stent placement can temporarily relieve the dysphagia symptoms with an acceptable risk (providing the procedure is handled by a center with plenty of experience), whereas repeated endoscopic dilations are not to be recommended, since they expose the patient to a risk of perforation at every session.
Given the high incidence of multiple metastatic lesions from breast cancer, surgical resection is not the treatment of choice as far as the esophagus is concerned, although there are reports of successful palliative resection with subtotal esophagectomy and gastrointestinal tract reconstruction. 14 Nowadays, most authors claim that hormone therapy may be effective in relieving dysphagia. Moreover, a diseasefree survival as long as 5 years has been reported with hormone therapy. 15, 16 Other authors have suggested that radiotherapy, with or without chemotherapy, should be the treatment of choice, given the relatively low risk for the patient and its effectiveness in relieving dysphagia. 17 In our experience, the preferred treatment shifted with time from endoscopic dilation or stent placement (with the related risk of severe complications, namely, esophageal perforation and tracheoesophageal fistula) toward hormone therapy or chemotherapy and/or radiotherapy, with improved survival rate from 4.5 to 16 months.
These data are confirmed by a recent report from the Mayo Clinic, 18 with 73 patients affected by gastrointestinal metastases and peritoneal carcinosis from breast cancer. Most of these patients were treated with systemic chemotherapy (59%) or hormonal therapy (56%). Chemotherapy and hormonal therapy significantly affected survival (P ϭ 0.02). Chemotherapy and hormonal therapy should be considered the initial treatment, when the diagnosis of mediastinal carcinosis from breast cancer is made, given that they significantly affect survival. On the other hand, endoscopic placement of a stent should be reserved to those patients who do not have a significant improvement of dysphagia after treatment, or in case a tracheoesophageal fistula, although it rarely develops.
Given that mediastinal carcinosis from breast cancer is considered an advanced-stage disease in any case and especially in patients with distant metastases at diagnosis, nutritional support with percutaneous endoscopic gastrostomy or surgical gastrostomy/jejunostomy (even with minimally invasive techniques, 19, 20 whenever possible) should be guaranteed to allow a decent quality of life.
CONCLUSION
Esophageal involvement from breast cancer is rare and its diagnosis is often a clinical challenge. A "breast-esophagus" syndrome can be described based on history of breast cancer, worsening dysphagia, typical radiologic pattern, and negative endoscopic biopsies with apparently normal esophageal mucosa. The diagnostic process ( Fig. 5 ) includes barium swallow, endoscopy with endosonography, chest-abdomen CT scans, and minimally invasive exploration, when necessary. These diagnostic tools may be helpful, although sometimes the diagnosis can be reached after exclusion of other diseases or after relieving dysphagia with ex adjuvantibus treatments. Finding a distant metastasis helps in diag-
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Breast-Esophagus Syndrome nosing mediastinal carcinosis, but in patients without any signs of distant spread an exploratory thoracoscopy or even EUS-FNAB (both in experienced centers) is needed to establish a definitive diagnosis. The current treatments of choice are hormone therapy or chemotherapy and/or radiotherapy, which have replaced endoscopic dilation and stent placement due to the high risk of complications related with the latter.
